PKO Investment Management Joint Stock Co Purchases 1,300 Shares of Danaher Corporation $DHR

PKO Investment Management Joint Stock Co boosted its stake in shares of Danaher Corporation (NYSE:DHR) by 11.1% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 13,000 shares of the conglomerate’s stock after purchasing an additional 1,300 shares during the period. PKO Investment Management Joint Stock Co’s holdings in Danaher were worth $2,568,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. GAMMA Investing LLC lifted its position in Danaher by 22.2% during the first quarter. GAMMA Investing LLC now owns 9,126 shares of the conglomerate’s stock valued at $1,871,000 after purchasing an additional 1,660 shares during the last quarter. Pacific Capital Partners Ltd bought a new stake in Danaher during the 1st quarter valued at about $7,175,000. GHP Investment Advisors Inc. increased its position in Danaher by 396.0% during the 1st quarter. GHP Investment Advisors Inc. now owns 124 shares of the conglomerate’s stock valued at $25,000 after purchasing an additional 99 shares during the period. International Assets Investment Management LLC grew its position in shares of Danaher by 39.5% in the 1st quarter. International Assets Investment Management LLC now owns 2,191 shares of the conglomerate’s stock worth $449,000 after buying an additional 620 shares during the last quarter. Finally, Golden State Wealth Management LLC grew its position in shares of Danaher by 356.0% in the 1st quarter. Golden State Wealth Management LLC now owns 611 shares of the conglomerate’s stock worth $125,000 after buying an additional 477 shares during the last quarter. 79.05% of the stock is currently owned by institutional investors.

Insider Transactions at Danaher

In other news, Director Teri List sold 2,778 shares of the firm’s stock in a transaction that occurred on Friday, August 22nd. The shares were sold at an average price of $211.06, for a total transaction of $586,324.68. Following the completion of the sale, the director owned 20,751 shares of the company’s stock, valued at approximately $4,379,706.06. This trade represents a 11.81% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 11.10% of the stock is owned by company insiders.

Danaher Price Performance

NYSE:DHR opened at $223.03 on Friday. The firm has a market cap of $157.54 billion, a price-to-earnings ratio of 45.99, a price-to-earnings-growth ratio of 3.41 and a beta of 0.77. The company has a current ratio of 1.52, a quick ratio of 1.22 and a debt-to-equity ratio of 0.33. The company’s 50-day moving average is $202.73 and its two-hundred day moving average is $198.36. Danaher Corporation has a 12-month low of $171.00 and a 12-month high of $258.23.

Danaher (NYSE:DHR) last released its earnings results on Tuesday, October 21st. The conglomerate reported $1.89 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.72 by $0.17. Danaher had a net margin of 14.44% and a return on equity of 10.92%. The company had revenue of $6.05 billion for the quarter, compared to analyst estimates of $6 billion. During the same period in the prior year, the firm earned $1.71 EPS. The firm’s quarterly revenue was up 4.4% on a year-over-year basis. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. Research analysts expect that Danaher Corporation will post 7.63 EPS for the current year.

Danaher Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Friday, September 26th will be given a $0.32 dividend. The ex-dividend date of this dividend is Friday, September 26th. This represents a $1.28 annualized dividend and a yield of 0.6%. Danaher’s dividend payout ratio (DPR) is 26.39%.

Analyst Upgrades and Downgrades

Several research firms have weighed in on DHR. Guggenheim reissued a “buy” rating and set a $250.00 target price on shares of Danaher in a research report on Wednesday, July 23rd. Rothschild & Co Redburn restated a “neutral” rating and set a $220.00 price objective (down from $245.00) on shares of Danaher in a research report on Wednesday, October 8th. JPMorgan Chase & Co. increased their target price on shares of Danaher from $260.00 to $270.00 and gave the company an “overweight” rating in a research report on Wednesday. Wall Street Zen cut shares of Danaher from a “buy” rating to a “hold” rating in a research report on Saturday. Finally, Royal Bank Of Canada set a $241.00 price objective on shares of Danaher in a research report on Tuesday, September 2nd. Eighteen analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $243.39.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.